(Q40162776)

English

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

The proteasome inhibitors bortezomib and PR-171 have antiproliferative and proapoptotic effects on primary human acute myeloid leukaemia cells (English)

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

1 reference

based on heuristic

inferred from title

Bjørn Tore Gjertsen

7

object named as

Bjørn Tore Gjertsen

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

author name string

Camilla Stapnes

1

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Anne P Døskeland

2

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Kimberley Hatfield

3

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Elisabeth Ersvaer

4

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Anita Ryningen

5

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

James B Lorens

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Oystein Bruserud

8

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

language of work or name

0 references

publication date

1 March 2007

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

British Journal of Haematology

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

136

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

6

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

814-828

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

Outcome after induction chemotherapy for older patients with acute myeloid leukemia is not improved with mitoxantrone and etoposide compared to cytarabine and daunorubicin: a Southwest Oncology Group study

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Cancer stem cells: AMLs show the way.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

NF-kappaB constitutes a potential therapeutic target in high-risk myelodysplastic syndrome

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Targeting NF-kappaB in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

New strategies in the treatment of acute myelogenous leukemia (AML): in vitro culture of aml cells--the present use in experimental studies and the possible importance for future therapeutic approaches.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Protein lysine acetylation in normal and leukaemic haematopoiesis: HDACs as possible therapeutic targets in adult AML.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

The ubiquitin-mediated protein degradation pathway in cancer: therapeutic implications

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Proteasome plasticity.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Preferential induction of apoptosis for primary human leukemic stem cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

The ubiquitin system for protein degradation and some of its roles in the control of the cell division cycle

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Bortezomib interactions with chemotherapy agents in acute leukemia in vitro

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Activity patterns of proteasome subunits reflect bortezomib sensitivity of hematologic malignancies and are variable in primary human leukemia cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Discovery of the ubiquitin proteasome system and its involvement in apoptosis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Proteasome inhibitors: antitumor effects and beyond

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Role of the proteasome and NF-kappaB in streptococcal cell wall-induced polyarthritis

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Proteasome inhibition as a novel therapeutic target in human cancer.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Stem cells, cancer, and cancer stem cells

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Clinical update: proteasome inhibitors in hematologic malignancies

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

In vitro crosstalk between fibroblasts and native human acute myelogenous leukemia (AML) blasts via local cytokine networks results in increased proliferation and decreased apoptosis of AML cells as well as increased levels of proangiogenic Interleu

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Adult acute myeloid leukaemia.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Histone deacetylase inhibitor depsipeptide (FK228) induces apoptosis in leukemic cells by facilitating mitochondrial translocation of Bax, which is enhanced by the proteasome inhibitor bortezomib.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

A simple, robust, validated and highly predictive index for the determination of risk-directed therapy in acute myeloid leukaemia derived from the MRC AML 10 trial

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Therapeutic potential of cytokine and chemokine antagonists in cancer therapy

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

The proteasome inhibitor bortezomib interacts synergistically with histone deacetylase inhibitors to induce apoptosis in Bcr/Abl+ cells sensitive and resistant to STI571.

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Regulation of apoptosis proteins in cancer cells by ubiquitin

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

The ubiquitin proteasome pathway from bench to bedside

1 reference

https://api.crossref.org/works/10.1111%2FJ.1365-2141.2007.06504.X

21 January 2018

Identifiers

10.1111/J.1365-2141.2007.06504.X

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

18 September 2017

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q40162776&oldid=1887796830"